PRESENTATION

Q3 2021 — Results presentation

Q3 2021PDF · 19 pages1.2 MB


-- 1 of 19 --

3rd Quarter 2021
Earnings Call
October 19, 2021

-- 2 of 19 --

Cautionary Note on Forward-looking Statements
3
This presentation contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things: future
operating and financial performance, product development, market position and business strategy. The reader is cautioned not to rely on these forward-looking
statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or
uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson. Risks and uncertainties include, but are not
limited to: risks related to the impact of the COVID-19 global pandemic, such as the scope and duration of the outbreak, government actions and restrictive measures
implemented in response, material delays and cancellations of medical procedures, supply chain disruptions and other impacts to the business, or on the Company’s
ability to execute business continuity plans, as a result of the COVID-19 pandemic; economic factors, such as interest rate and currency exchange rate fluctuations;
competition, including technological advances, new products and patents attained by competitors; challenges inherent in new product research and development,
including uncertainty of clinical success and obtaining regulatory approvals; uncertainty of commercial success for new and existing products; challenges to patents; the
impact of patent expirations; the ability of the Company to successfully execute strategic plans; the impact of business combinations and divestitures; manufacturing
difficulties or delays, internally or within the supply chain; product efficacy or safety concerns resulting in product recalls or regulatory action; significant adverse litigation
or government action, including related to product liability claims; changes to applicable laws and regulations, including tax laws and global health care reforms; trends
toward health care cost containment; changes in behavior and spending patterns of purchasers of health care products and services; financial instability of international
economies and legal systems and sovereign risk; increased scrutiny of the health care industry by government agencies. A further list and descriptions of these risks,
uncertainties and other factors can be found in Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended January 3, 2021, including in the sections
captioned “Cautionary Note Regarding Forward-Looking Statements” and “Item 1A. Risk Factors,” in the Company’s most recently filed Quarterly Report on Form 10-Q
and the Company’s subsequent filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com or on
request from Johnson & Johnson. Any forward-looking statement made in this presentation speaks only as of the date of this presentation. Johnson & Johnson does not
undertake to update any forward-looking statement as a result of new information or future events or developments.
Cautionary Note on Non-GAAP Financial Measures
This presentation refers to certain non-GAAP financial measures. These non-GAAP financial measures should not be considered replacements for, and should be read
together with, the most comparable GAAP financial measures.
A reconciliation of these non-GAAP financial measures to the most directly comparable GAAP financial measures can be found in the accompanying financial
schedules of the earnings release and the Investor Relations section of the Company’s website at www.investor.jnj.com.

-- 3 of 19 --

Immunology REMICADE and SIMPONI/ SIMPONI ARIA marketing partners are Schering-Plough (Ireland) Company, a subsidiary of Merck & Co., Inc. and Mitsubishi Tanabe Pharma Corporation, and TREMFYA
discovered using MorphoSys AG antibody technology
Neuroscience INVEGA SUSTENNA/ XEPLION/ INVEGA TRINZA/ TREVICTA/ INVEGA HAFYERA are subject to a technology license agreement from Alkermes Pharma Ireland Limited, and RISPERDAL
CONSTA developed in collaboration with Alkermes, Inc.
Infectious Diseases
PREZCOBIX / REZOLSTA fixed-dose combination, SYMTUZA and ODEFSEY developed in collaboration with Gilead Sciences, Inc., and JULUCA and CABENUVA developed in collaboration with
ViiV Healthcare UK. Research and development activities for the Company’s COVID-19 vaccine, including the ENSEMBLE clinical trial and the delivery of doses for the U.S., has been funded in part
with federal funds from the U.S. Department of Health and Human Services, Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development
Authority (BARDA), under Contract No. HHSO100201700018C, and in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH)
at the U.S. Department of Health and Human Services (HHS)
Cardiovascular/
Metabolism/Other
INVOKANA/ INVOKAMET/ VOKANAMET/ INVOKAMET XR fixed-dose combination licensed from Mitsubishi Tanabe Pharma Corporation, XARELTO co-developed with Bayer HealthCare AG,
PROCRIT/ EPREX licensed from Amgen Inc., and X-Linked Retinitis Pigmentosa: AAV-RPGR licensed from MeiraGTx
Oncology
IMBRUVICA developed in collaboration and co-marketed in the U.S. with Pharmacyclics, LLC, an AbbVie company, ZYTIGA licensed from BTG International Ltd., VELCADE developed in
collaboration with Millennium: The Takeda Oncology Company, DARZALEX and DARZALEX FASPRO licensed from Genmab A/S, BALVERSA licensed and discovered in collaboration with Astex
Pharmaceuticals, Inc., ERLEADA is licensed from Regents of California and Memorial Sloan Kettering, cilta-cel licensed and developed in collaboration with Legend Biotech USA Inc. and Legend
Biotech Ireland Limited, niraparib licensed from TESARO, Inc., an oncology-focused business within GSK, lazertinib licensed from Yuhan Corporation, DuoBody platform licensed from Genmab A/S
relates to several bispecific antibody programs, ENHANZE platform licensed from Halozyme Therapeutics, Inc.
Pulmonary Hypertension UPTRAVI license and supply agreement with Nippon Shinyaku (co-promotion in Japan), and OPSUMIT co-promotion agreement with Nippon Shinyaku in Japan
Global Public Health
Janssen’s Monovalent Ebola Vaccine is developed in collaboration with Bavarian Nordic A/S, and MVA-BN-Filo® is licensed-in from Bavarian Nordic A/S. The program has benefited from funding
and preclinical services from the National Institute of Allergy and Infectious Diseases (NIAID), part of NIH, NIAID support included 2 product development contracts starting in 2008 and 8 pre-clinical
services contracts. This program is also receiving funding from the IMI2 Joint Undertaking under EBOVAC1 (grant nr. 115854), EBOVAC2 (grant nr. 115861), EBOVAC3 (grant nr. 800176), EBOMAN
(grant nr. 115850) and EBODAC (grant nr. 115847). The IMI2 Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation program and the European
Federation of Pharmaceutical Industries and Associations (EFPIA). Further funding for the Ebola vaccine regimen has been provided by the BARDA, within the U.S. Department of Health and Human
Services’ Office of the Assistant Secretary for Preparedness and Response, under Contract Numbers HHSO100201700013C and HHSO100201500008C.. The initial work on Ebola was conducted
which was extended from 2002 until 2011. 2002 and 2007 via a Cooperative Research and Development Agreement (CRADA is AI-0114) between Janssen/Crucell and the Vaccine Research Center
(VRC)/NIAID, part of the NIH. Janssen/Crucell have licenses to much of VRC’s Ebola IP specific for human adenovirus under the Ad26/Ad35 Ebola vaccine CRADA invention. VAC69120 (Filovirus
multivalent vaccine) developed in collaboration with Bavarian Nordic; funding: NIH Division of Microbiology and Infectious Diseases (DMID), under Contract Number HHSN272200800056C.
Strategic Partnerships,
Collaborations & Licensing Arrangements
4
During the course of this morning’s presentation, we will discuss a number of products and compounds developed in collaboration with strategic
partners or licensed from other companies. The following is an acknowledgement of those relationships:

-- 4 of 19 --

Enterprise Highlights
Sales Performance and Earnings Review
Capital Allocation and Guidance
Q&A
5
Agenda
1
2
3
4
Ashley McEvoy
Executive Vice President
Worldwide Chairman,
Medical Devices
Thibaut Mongon
Executive Vice President
Worldwide Chairman,
Consumer Health
Jennifer Taubert
Executive Vice President
Worldwide Chairman,
Pharmaceuticals
Joseph J. Wolk
Executive Vice President
Chief Financial Officer

-- 5 of 19 --

Regional Sales Results Q3 2021 Q3 2020
% CHANGE
Reported Operational1
U.S. $12.0 $11.1 7.9% 7.9%
Europe 5.6 4.8 15.9 14.6
Western Hemisphere
(ex U.S.) 1.5 1.3 15.7 13.4
Asia-Pacific, Africa 4.3 3.9 10.5 8.5
International 11.4 10.0 13.8 12.1
Worldwide (WW) $23.3 $21.1 10.7% 9.9%
1 Non-GAAP measure; excludes the impact of translational currency; see reconciliation schedules in the Investors section of the company's website
2 Note: Values may not add due to rounding
3rd Quarter 2021 Sales
Dollars in Billions
6

-- 6 of 19 --

18.2%; 16.4%1
Q3 2021 Q3 2020
$2.60
$2.20
3rd Quarter 2021 Financial Highlights
Dollars in Billions, except EPS
Reported %; Operational %1
7
Sales
Adjusted Earnings2 Adjusted EPS2
10.7%; 9.9%1
$23.3
$21.1
GAAP Earnings
3.2%
$3.7 $3.6
18.7%
Q3 2021 Q3 2020
GAAP EPS
3.0%
$1.37 $1.33
Q3 2021	Q3 2021 Q3 2020 Q3 2020	Q3 2021 Q3 2020
$7.0
$5.9
1 Non-GAAP measure; excludes the impact of translational currency; see reconciliation schedules in the Investors section of the company's website
2 Non-GAAP measure; excludes intangible amortization expense and special items; see reconciliation schedules in the Investors section of the company's website

-- 7 of 19 --

OTC
$1,372 Skin Health/Beauty
$1,124
Oral Care
$398
Baby Care
$391
Women's Health
$232
Wound Care/Other
$182
$3,700
5.3%, 4.1%
WW Sales $MM
■ Reported Growth ■ Operational Growth1
Consumer Health Highlights – 3rd Quarter 2021
Strong growth primarily driven by OTC
8
Key Drivers of Operational Performance1
OTC
• Growth driven by increased pediatric fever incidences, category recovery for Cough, Cold & Flu
and Digestive Health, as well as U.S. share gains across multiple brands. Outside the U.S.,
TYLENOL vaccine symptom relief usage mostly in Korea, MOTRIN consumption increases in
China, and ORSL HCP COVID-19 symptom relief recommendations also drove growth.
Skin Health/
Beauty
• Decline driven by DR. CI LABO - Sedona divestiture in ASPAC, U.S. external supply
constraints and Sun aerosol recall partially offset by WW COVID-19 recovery and e-commerce
growth as well as strong OUS performance of AVEENO and NEUTROGENA
Oral Care
• Decline driven by divestiture and U.S. external supply constraints partially offset by market
growth in the U.S. along with strong performance in ASPAC due to successful brand building
and promotional campaigns
Baby Care • Decline driven by COVID-19 related lockdowns in parts of ASPAC coupled with competitive
pressures in that region partially offset by WW AVEENO Baby strength
Women’s
Health
• Growth driven by COVID-19 market recovery, favorable price in LATAM offset by disruptions in
EMEA due to flooding
Wound
Care/Other
• Decline driven by lapping prior year stocking, OUS competitive pressures partially offset by
U.S. category growth
Adjusted Operational Sales2: WW 5.7%, U.S. 5.1%, Int’l 6.1%
Reported: WW 5.3%, U.S. 4.5%, Int’l 5.9%
Operational1: WW 4.1%, U.S. 4.5%, Int’l 3.7%
1 Non-GAAP measure; excludes the impact of translational currency; see reconciliation schedules in the Investors section of the company's website
2 Non-GAAP measure; excludes acquisitions and divestitures and translational currency; see reconciliation schedules in the Investors section of the company's website
Note: Values may not add due to rounding
20.1%, 18.2%
0.8%, 0.8%
(3.5)%, (4.8)%
(0.3)%, (1.2)%
(3.3)%, (4.5)%
(2.2)%, (3.0)%

-- 8 of 19 --

Key Drivers of Operational Performance1
Immunology
• Growth driven by continued strong uptake of STELARA in Crohn’s Disease and
Ulcerative Colitis, strength of TREMFYA in Psoriasis and uptake in Psoriatic Arthritis,
and market/share gains in SIMPONI ARIA
• REMICADE decline due to biosimilar competition
Infectious
Diseases
• Growth driven by the contribution of the COVID-19 vaccine
• Partially offset by increased competition for PREZISTA/PREZCOBIX/REZOLSTA and
PREZISTA OUS LOE
Neuroscience
• Paliperidone long-acting injectables growth due to strength of INVEGA
SUSTENNA/XEPLION and INVEGA TRINZA/TREVICTA from new patient starts and
persistency
Oncology
• DARZALEX increase driven by continued strong market growth and share gains in all
regions and solid uptake of the subcutaneous formulation launched in 2020
• IMBRUVICA growth primarily driven by market and continued share leadership, partially
offset by COVID-19 related market dynamics including continued delays in new patient
starts as well as competitive pressures and a one-time prior period adjustment
• Continued strong global launch uptake of ERLEADA
Cardiovascular/
Metabolism/
Other (CVM/Other)
• Decline driven by lower sales of PROCRIT/EPREX due to biosimilar competition
• INVOKANA/INVOKAMET decline due to continued share erosion
Pulmonary
Hypertension (PH)
• Growth driven by strong sales of OPSUMIT and UPTRAVI due to continued share gains
and market growth
Adjusted Operational Sales2: WW 13.8%, U.S. 12.2%, Int’l 16.0%	Immunology
$4,250
Infectious Diseases
$1,389
Neuroscience
$1,689
Oncology
$3,665 CVM/Other
$1,133
PH
$868
$12,994
13.8%, 13.2%
WW Sales $MM
■ Reported Growth ■ Operational Growth1
Pharmaceutical Highlights – 3rd Quarter 2021
9
Reported: WW 13.8%, U.S. 12.2%, Int’l 15.9%
Operational1: WW 13.2%, U.S. 12.2%, Int’l 14.6%
1 Non-GAAP measure; excludes the impact of translational currency; see reconciliation schedules in the Investors section of the company's website
2 Non-GAAP measure; excludes acquisitions and divestitures and translational currency; see reconciliation schedules in the Investors section of the company's website
Note: Values may not add due to rounding
(11.5)%, (12.4)%
15.9%, 16.1%
17.1%, 16.5%
5.3%, 4.6%
60.6%, 59.8%
12.2%, 11.7%
Continued above-market performance driven by double-digit growth in key products

-- 9 of 19 --

Orthopaedics
$2,093
Surgery
$2,405
Vision
$1,189
Interventional
Solutions
$957
$6,644
8.0%, 7.0%
WW Sales $MM
■ Reported Growth ■ Operational Growth1
Medical Devices Highlights – 3rd Quarter 2021
Growth primarily driven by COVID-19 related market recovery and innovation
10
Reported: WW 8.0%, U.S. 0.8%, Int’l 15.4%
Operational1: WW 7.0%, U.S. 0.8%, Int’l 13.3%
Key Drivers of Operational Performance1
Interventional
Solutions
• Market recovery, success of new products (VIZIGO and CARTO V7) and commercial
strategies continuing to enhance global leadership
Orthopaedics
• Hips: Growth reflects market recovery combined with continued strength of our portfolio
including the ACTIS stem aided by enabling technologies – KINCISE and VELYS Hip
Navigation
• Trauma: Growth reflects global market recovery and uptake of new products including
Cannulated Compression Headless Screws, Advanced Nailing Systems and Fibulink
• Knees: Growth primarily driven by procedure recovery and timing of an OUS tender
• Spine, Sports & Other: Decline driven primarily by COVID-19 related impacts on the
market partially offset by new products (CONDUIT and VIPER Prime)
• Spine: WW: ~-11%, U.S.: ~-14%, OUS: ~-7%
Surgery
• Advanced:
• Endocutters: ~+12% Driven by market recovery and new products (ECHLON Staple
Line Reinforcement) offsetting competitive pressure in the U.S.
• Biosurgery: ~+13% Market recovery and share expansion driven by success of newer
products (VISTASEAL and SURGICEL POWDER) and Asia Pacific market expansion
• Energy: ~+13% Primarily due to market recovery, new products and market expansion
offsetting competitive pressures in the U.S.
• General: Growth primarily driven by market recovery and continued strength of the Suture
portfolio
Vision
• Contact Lenses/Other: Growth driven primarily by market recovery and new products
(ACUVUE OASYS Multifocal and ACUVUE Define Fresh) partially offset by prior year higher
level of stocking in the U.S.
• Surgical: Growth primarily due to market recovery & uptake of recently launched products
(TECNIS Eyhance and TECNIS Synergy)
Adjusted Operational Sales2: WW 7.6%, U.S. 1.1%, Int’l 14.1%
1 Non-GAAP measure; excludes the impact of translational currency; see reconciliation schedules in the Investors section of the company's website
2 Non-GAAP measure; excludes acquisitions and divestitures and translational currency; see reconciliation schedules in the Investors section of the company's website
Note: Values may not add due to rounding
14.5%, 13.2%
10.1%, 10.0%
0.5%, (0.3)%
11.8%, 10.2%

-- 10 of 19 --

2021 2020 %
Increase
(Decrease)	Amount % to Sales Amount % to Sales
Sales to customers $23,338 100.0 $21,082 100.0 10.7
Cost of products sold 7,250 31.1 6,972 33.1 4.0
Gross Profit 16,088 68.9 14,110 66.9 14.0
Selling, marketing and administrative expenses 6,000 25.7 5,431 25.8 10.5
Research and development expense 3,422 14.7 2,840 13.5 20.5
In-process research and development 900 3.9 138 0.6
Interest (income) expense, net 7 0.0 32 0.1
Other (income) expense, net 1,850 7.9 1,200 5.7
Restructuring 60 0.2 68 0.3
Earnings before provision for taxes on income 3,849 16.5 4,401 20.9 (12.5)
Provision for taxes on income 182 0.8 847 4.0 (78.5)
Net Earnings $3,667 15.7 $3,554 16.9 3.2
-
Net earnings per share (Diluted) $1.37 $1.33 3.0
Average shares outstanding (Diluted) 2,674.9 2,669.3
Effective tax rate 4.7% 19.2%
.
Adjusted earnings before provision for taxes and net earnings1
Earnings before provision for taxes on income $8,058 34.5 $7,246 34.4 11.2
Net earnings $6,968 29.9 $5,868 27.8 18.7
Net earnings per share (Diluted) $2.60 $2.20 18.2
Effective tax rate 13.5% 19.0%
Condensed Consolidated Statement of Earnings
1 Non-GAAP measure; excludes intangible amortization expense and special items; see reconciliation schedules in the Investors section of the company's website 11
3rd Quarter 2021
(Unaudited; Dollar and Shares in Millions Except Per Share Figures)

-- 11 of 19 --

2021 2020
Adjusted Income Before Tax by Segment1
3rd Quarter 2021
12
Pharmaceutical
Medical Devices
Consumer Health
Expenses Not Allocated to Segments
3Q 2021 3Q 2020
Pharmaceutical 43.9% 46.4%
Medical Devices 25.5% 21.6%
Consumer Health 23.3% 24.4%
Total 34.5% 34.4%
1 Non-GAAP measure; excludes amortization expense and special items; see reconciliation schedules in the Investors section of the company's website
2 Estimated as of 10/19/2021
% to Sales
($0.2)	($0.2)
$7.2B
$5.3
$0.9
$8.1B
$5.7
$1.7
$0.9
2
$1.3

-- 12 of 19 --

Joseph J. Wolk
Executive Vice President,
Chief Financial Officer

-- 13 of 19 --

Notable New Announcements in 3rd Quarter 20211
Pharmaceutical
• Regulatory Decisions:
– INVEGA HAFYERA (paliperidone palmitate) Receives FDA Approval For First and Only Twice-Yearly Treatment for Adults with Schizophrenia
– XARELTO (rivaroxaban) Plus Aspirin Receives FDA Approval For Expanded Peripheral Artery Disease (PAD) Indication to Include Patients After Lower-Extremity Revascularization (LER)
– UPTRAVI (selexipag) Receives FDA Approval For Intravenous Use in Adult Patients with Pulmonary Arterial Hypertension (PAH)
• Regulatory Submission:
– Johnson & Johnson Announces Submission of Emergency Use Authorization Amendment to the U.S. FDA to Support Booster of its Single-Shot COVID-19 Vaccine2
– Janssen Submits Application Seeking U.S. FDA Approval of STELARA (ustekinumab) for the Treatment of Pediatric Patients With Juvenile Psoriatic Arthritis2
• Other:
– Johnson & Johnson Announces Real-World Evidence and Phase 3 Data Confirming Strong and Long-Lasting Protection of Single-Shot COVID-19 Vaccine in the U.S.
– Johnson & Johnson Issues Statement on Nationwide Opioid Settlement Agreement
– Janssen Announces Start of Phase 3 Trial for Investigational Respiratory Syncytial Virus (RSV) Vaccine in Older Adults
– Janssen Receives Positive CHMP Opinion for BYANNLI (six-monthly paliperidone palmitate) for the Maintenance Treatment of Schizophrenia in Adults
– Janssen Receives Positive CHMP Opinion for RYBREVANT (amivantamab) for the Treatment of Patients with Advanced Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations After Failure of
Platinum-Based Therapy2
– Johnson & Johnson COVID-19 Vaccine Booster Shot Unanimously Recommended for Emergency Use Authorization by U.S. FDA Advisory Committee2
Medical Devices
• Other
– DePuy Synthes Announces Introduction of the INHANCE Shoulder System, a First-to-Market, Fully Integrated Shoulder Arthroplasty System
– Ethicon Announces ECHELON CIRCULAR Powered Stapler Associated with Major Reduction in Serious Complications Following Colorectal Surgery
Enterprise
• Other
– Alex Gorsky to Transition Role of Chief Executive Officer of Johnson & Johnson to Joaquin Duato, Effective January 3, 2022
– Dr. Paul Stoffels, Vice Chairman of the Executive Committee and Chief Scientific Officer of Johnson & Johnson to Retire, Effective December 31, 20212
– Johnson & Johnson Takes Steps to Equitably Resolve All Current and Future Talc Claims2
14
1 These developments and all other news releases are available online in the Investors section of the company’s website at news releases
2 Subsequent to the quarter

-- 14 of 19 --

Capital Allocation Strategy
Capital Allocation
Organic growth business needs
Free cash flow1
Priorities are clear and remain unchanged
Competitive dividends
Share repurchases
HIGHER
PRIORITY
LOWER
PRIORITY
Investment in M&A
Dollars in Billions Q3 2021
Cash and Marketable
Securities $31
Debt ($34)
Net Debt ($3)
Free Cash Flow2 ~$15
Q3 2021:
$3.4B invested in R&D
$2.8B in dividends paid
to shareholders
Note: values may have been rounded
1 Non-GAAP measure; cash flow from operations less CAPEX
2 Estimated as of October 19, 2021 15

-- 15 of 19 --

1 Non-GAAP measure; excludes acquisitions and divestitures
2 Non-GAAP measure; excludes the impact of translational currency
3 Euro Average Rate: October 2021 = $1.19; Euro Spot Rate: October 2021 = $1.16
Note: Percentages may be rounded. 16
October (Base Business) July (Base Business) Comments
Adjusted Operational Sales1,2 9.9% - 10.5% 9.5% - 10.5% Tightening of range and
strong base performance
Operational Sales2 $90.3B - $90.8B
9.4% – 10.0%
$90.0B - $90.8B
9.0% – 10.0% Midpoint of 9.7%
Estimated Reported Sales3 $91.6B - $92.1B
10.9% – 11.5%
$91.3B - $92.1B
10.5% – 11.5%
Midpoint of $91.9B or 11.2%
FX $1.3B or 1.5% impact
2021 Revenue Guidance
October (Incl. COVID-19
Vaccine)
July (Incl. COVID-19
Vaccine) Comments
Adjusted Operational Sales1,2 12.9% - 13.5% 12.5% - 13.5%
Maintaining Full Year
COVID-19 Vaccine sales
estimate of ~$2.5B
Operational Sales2 $92.8B - $93.3B
12.4% – 13.0%
$92.5B - $93.3B
12.0% – 13.0%
Estimated Reported Sales3 $94.1B - $94.6B
13.9% – 14.5%
$93.8B - $94.6B
13.5% – 14.5%

-- 16 of 19 --

1 Non-GAAP measure; excludes acquisitions and divestitures 4 Non-GAAP measure; excludes intangible amortization expense and special items
2 Non-GAAP measure; excludes the impact of translational currency 5 Sales less: COGS, SM&A and R&D expenses
3 Euro Average Rate: October 2021 = $1.19; Euro Spot Rate: October 2021 = $1.16
Note: Percentages may be rounded. 17
October (Incl. COVID-19
Vaccine)
July (Incl. COVID-19
Vaccine) Comments
Adjusted Operational Sales1,2 12.9% - 13.5% 12.5% - 13.5% Tightening of range and
strong base performance
Operational Sales2 $92.8B - $93.3B
12.4% – 13.0%
$92.5B - $93.3B
12.0% – 13.0% Midpoint of 12.7%
Estimated Reported Sales3 $94.1B - $94.6B
13.9% – 14.5%
$93.8B - $94.6B
13.5% – 14.5%
Midpoint of $94.4B or 14.2%
FX $1.3B or 1.5% impact
Adjusted Pre-Tax
Operating Margin4,5 Nearly 200 bps improvement Nearly 200 bps improvement
Net Other Income4 $0.9 - $0.95 billion $0.8 - $0.9 billion Increasing & tightening based
on year-to-date trends
Net Interest Expense /
(Income) $100 - $150 million $100 - $200 million Tightening based on year-to-date trends
Effective Tax Rate4 14.5% - 15.5% 16.0% - 17.0% Lowering of range due to
certain one-time benefits
Adjusted EPS (Operational)2,4 $9.65 - $9.70
20.2% - 20.8%
$9.50 - $9.60
18.4% - 19.6%
Tightening of range to $0.05 &
increasing midpoint by $0.13
Adjusted EPS (Reported)3,4 $9.77 - $9.82
21.7% - 22.3%
$9.60 - $9.70
19.6% - 20.8%
Midpoint of $9.80 or 22.0%
FX $0.12 or 1.5% impact
2021 P&L Guidance

-- 17 of 19 --

Q&A
Jennifer Taubert
Executive Vice President
Worldwide Chairman,
Pharmaceuticals
Executive Vice President
Worldwide Chairman,
Medical Devices
Ashley McEvoy Joseph J. Wolk
Executive Vice President,
Chief Financial Officer
Thibaut Mongon
Executive Vice President
Worldwide Chairman,
Consumer Health

-- 18 of 19 --



-- 19 of 19 --